Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSPO1-neutralizing antibody
- Development stage
- Preclinical
- Lead developer
- Ruijin Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
RSPO1-neutralizing antibody is a therapeutic monoclonal antibody designed to inhibit R-spondin 1 (RSPO1), a protein significantly upregulated following myocardial infarction (MI). RSPO1 acts through the LGR4-β-catenin-IRF7 signaling axis to drive the polarization of macrophages toward a pro-inflammatory phenotype, which contributes to adverse ventricular remodeling and the progression of heart failure. By neutralizing RSPO1, the antibody reduces the expression of interferon-stimulated genes and attenuates cardiac dysfunction. Developed by researchers at Ruijin Hospital, this agent has demonstrated efficacy in preclinical models, suggesting its potential as a strategy for treating post-MI heart failure and preventing pathological cardiac remodeling.
- Other names
- anti-RSPO1 antibodyanti-RSPO-1 antibodyanti-RSPO 1 antibodyanti-R-spondin-1 antibodyanti-R-spondin1 antibodyanti-R-spondin 1 antibody
02
Targets
RSPO1 (R-spondin 1 / RSPO1)
Beyond the preview
Go deeper on RSPO1-neutralizing antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSPO1-neutralizing antibody.